2 research outputs found
Analyse des pratiques concernant les limitations et arrĂȘts des thĂ©rapeutiques actives en rĂ©animation neurochirurgicale entre 2013 et 2016 au CHU de Rouen
Les dĂ©cisions de limitations et arrĂȘts des thĂ©rapeutiques (LAT) actives sont une pratique courante en rĂ©animation neurochirurgicale. Elles bĂ©nĂ©ficient dâun cadre juridique et Ă©thique ainsi que de fiches dĂ©diĂ©es. Objectif: Cette Ă©tude avait pour objectif de connaĂźtre le taux de fiches remplies pour chaque patient et dâanalyser les facteurs limitants lâutilisation de cette fiche. Patients et mĂ©thodes: Nous avons menĂ© une Ă©tude rĂ©trospective, monocentrique. Ont Ă©tĂ© inclus tous les patients dĂ©cĂ©dĂ©s entre 2013 et 2016 et ayant la notification dâune limitation thĂ©rapeutique au sein du dossier mĂ©dical. En parallĂšle, un audit des personnels mĂ©dicaux et paramĂ©dicaux a Ă©tĂ© rĂ©alisĂ© afin de connaĂźtre leur vision de la pratique des LAT. Le critĂšre de jugement principal Ă©tait le taux de fiches remplies pour les patients ayant une LAT. Les critĂšres secondaires Ă©taient de connaitre les facteurs limitant lâutilisation de la fiche, de vĂ©rifier leur bonne rĂ©daction et de faire une mise au point concernant la vision du personnel concernant les LAT. RĂ©sultats: Entre mai 2013 et aoĂ»t 2016, 58,70% des patients dĂ©cĂ©dĂ©s ont fait lâobjet dâune procĂ©dure de LAT. Parmi eux, 53,84% (n=49) ont bĂ©nĂ©ficiĂ© de la rĂ©daction dâune fiche. Les facteurs identifiĂ©s comme limitant lâutilisation de la fiche sont la gravitĂ© neurologique initiale (Glasgow: 6 vs 4; p Conclusion: Lâutilisation de la fiche permet dâamĂ©liorer les pratiques et doit devenir systĂ©matique pour chaque patient faisant lâobjet dâune dĂ©cision de LAT. ConnaĂźtre les facteurs qui restreignent son utilisation permettra, Ă lâavenir, de limiter le nombre de patients sans fiche et dâavoir une meilleure adĂ©quation au cadre Ă©thique et lĂ©gal recommandĂ© dans ces situations
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial
International audienceBackground: Optimisation of brain oxygenation might improve neurological outcome after traumatic brain injury. The OXY-TC trial explored the superiority of a strategy combining intracranial pressure and brain tissue oxygen pressure (PbtO2) monitoring over a strategy of intracranial pressure monitoring only to reduce the proportion of patients with poor neurological outcome at 6 months.Methods: We did an open-label, randomised controlled superiority trial at 25 French tertiary referral centres. Within 16 h of brain injury, patients with severe traumatic brain injury (aged 18-75 years) were randomly assigned via a website to be managed during the first 5 days of admission to the intensive care unit either by intracranial pressure monitoring only or by both intracranial pressure and PbtO2 monitoring. Randomisation was stratified by age and centre. The study was open label due to the visibility of the intervention, but the statisticians and outcome assessors were masked to group allocation. The therapeutic objectives were to maintain intracranial pressure of 20 mm Hg or lower, and to keep PbtO2 (for those in the dual-monitoring group) above 20 mm Hg, at all times. The primary outcome was the proportion of patients with an extended Glasgow Outcome Scale (GOSE) score of 1-4 (death to upper severe disability) at 6 months after injury. The primary analysis was reported in the modified intention-to-treat population, which comprised all randomly assigned patients except those who withdrew consent or had protocol violations. This trial is registered with ClinicalTrials.gov, NCT02754063, and is completed.Findings: Between June 15, 2016, and April 17, 2021, 318 patients were randomly assigned to receive either intracranial pressure monitoring only (n=160) or both intracranial pressure and PbtO2 monitoring (n=158). 27 individuals with protocol violations were not included in the modified intention-to-treat analysis. Thus, the primary outcome was analysed for 144 patients in the intracranial pressure only group and 147 patients in the intracranial pressure and PbtO2 group. Compared with intracranial pressure monitoring only, intracranial pressure and PbtO2 monitoring did not reduce the proportion of patients with GOSE score 1-4 (51% [95% CI 43-60] in the intracranial pressure monitoring only group vs 52% [43-60] in the intracranial pressure and PbtO2 monitoring group; odds ratio 1·0 [95% CI 0·6-1·7]; p=0·95). Two (1%) of 144 participants in the intracranial pressure only group and 12 (8%) of 147 participants in the intracranial pressure and PbtO2 group had catheter dysfunction (p=0.011). Six patients (4%) in the intracranial pressure and PbtO2 group had an intracrebral haematoma related to the catheter, compared with none in the intracranial pressure only group (p=0.030). No significant difference in deaths was found between the two groups at 12 months after injury. At 12 months, 33 deaths had occurred in the intracranial pressure group: 25 (76%) were attributable to the brain trauma, six (18%) were end-of-life decisions, and two (6%) due to sepsis. 34 deaths had occured in the intracranial pressure and PbtO2 group at 12 months: 25 (74%) were attributable to the brain trauma, six (18%) were end-of-life decisions, one (3%) due to pulmonary embolism, one (3%) due to haemorrhagic shock, and one (3%) due to cardiac arrest.Interpretation: After severe non-penetrating traumatic brain injury, intracranial pressure and PbtO2 monitoring did not reduce the proportion of patients with poor neurological outcome at 6 months. Technical failures related to intracerebral catheter and intracerebral haematoma were more frequent in the intracranial pressure and PbtO2 group. Further research is needed to assess whether a targeted approach to multimodal brain monitoring could be useful in subgroups of patients with severe traumatic brain injury-eg, those with high intracranial pressure on admission